Summary
The AI statements concern Tradjenta savings card availability/eligibility rules in 2026 and Medicare/Medicaid acceptance/rejection. The provided FDA prescribing information excerpts contain no information about savings cards, payment programs, insurance eligibility, Medicare/Medicaid restrictions for coupons, start/end dates, or rejection rules; therefore the claims cannot be supported or verified against the supplied label text and appear label-unspecified.
Category Scores
Accurate Statements
Unsupported Statements
Whether a Tradjenta savings card will work in 2026 depends on the program’s current availability and the user’s eligibility under the program’s rules, including insurance type (e.g., commercial insurance vs. no insurance) and restrictions related to government programs.
The supplied FDA prescribing information excerpts do not include any claims or rules about savings card availability, eligibility criteria, insurance-type restrictions, government-program restrictions, or year-specific (2026) use.
Most drug savings cards are issued by the drug manufacturer or a savings-card program and typically include specific enrollment rules, eligibility limits, and start/end dates.
Not addressed in the provided FDA prescribing information excerpts.
Tradjenta savings cards may have restrictions on use with Medicare (and sometimes Medicaid).
No information in the supplied FDA prescribing information excerpts about Medicare/Medicaid restrictions on savings-card use.
Tradjenta savings cards may be rejected for Medicare Part D patients depending on the card’s current terms.
The provided FDA prescribing information excerpts contain no statements about rejection of savings cards for Medicare Part D patients or conditional acceptance based on terms.
Tradjenta savings cards may include exclusions related to government program coverage depending on the card’s current terms.
The provided FDA prescribing information excerpts contain no information about exclusions for government-program coverage within savings cards.
Contradictions
Important Omissions
Savings-card program details referenced by the AI statements (e.g., manufacturer participation, Medicare/Medicaid eligibility restrictions, Part D acceptance/rejection rules, and start/end dates) are not provided in the supplied FDA label excerpts, so the AI response cannot be verified for accuracy against the label.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Because the statements are not supported by (and cannot be verified against) the supplied FDA prescribing information regarding savings-card eligibility/acceptance, reliance on them could mislead patients about access to therapy costs/coverage. The label-based audit cannot confirm correctness.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
The AI response makes savings-card/insurance-eligibility claims that are absent from the provided FDA prescribing information excerpts.
Suggested Improvement
Limit the response to what the supplied FDA label actually covers (indication, dosing, contraindications, and labeled warnings/precautions). If savings-card questions are needed, reference the official savings-card program terms/website or manufacturer materials rather than the FDA prescribing information.